DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH in the United States, as well as future commercialization activities across new products and markets.
"We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. "Her deep expertise across the commercial spectrum-particularly in anti-infectives-will be instrumental as we aim to accelerate launch readiness for ORLYNVAH and scale our capabilities for long-term growth."
Ms. Coyne brings more than 30 years of commercial and operational experience in the pharmaceutical industry. Most recently, she served as Chief Commercial Officer at Innoviva, where she led the development and execution of go-to-market strategies across the company's infectious disease and critical care portfolio. Prior to Innoviva, Ms. Coyne held the role of Chief Commercial Officer at SCYNEXIS, where she successfully led the company's anti-infective portfolio and built its commercial infrastructure from the ground up. Her career also includes senior commercial leadership roles at Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo, and Wyeth/Pfizer.
"I'm honored to join Iterum at such an important moment for both the company and the patients we aim to serve," said Ms. Coyne. "The upcoming U.S. launch of ORLYNVAH represents a significant opportunity to bring innovation to an area with considerable unmet need, and I look forward to leading the team to deliver a successful launch and position Iterum for sustained growth."
Ms. Coyne holds a Bachelor of Arts from West Chester University and a Master of Business Administration from Eastern University.
About Iterum Therapeutics plc
Iterum is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
About ORLYNVAH
ORLYNVAH is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins.
Cautionary Note Regarding Forward-looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH, and Iterum's ability to prepare and implement commercialization plans for ORLYNVAH and to bring ORLYNVAHTM to market in the U.S. in the next quarter. In some cases, forward-looking statements can be identified by words such as "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "would," "will," "future," "potential" or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including Iterum's ability to raise sufficient capital and successfully prepare and implement commercialization plans for ORLYNVAH with its commercialization partner, EVERSANA, including Iterum's ability to, with the support of EVERSANA, build and maintain a sales force and prepare for a potential commercial launch of ORLYNVAH, the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if Iterum is unsuccessful at implementing commercialization plans for ORLYNVAH, the market opportunity for and the potential market acceptance of ORLYNVAH for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption "Risk Factors" in its Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025, and other documents filed with the Securities and Exchange Commission from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
